SLN.L Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 saus. 1970 @ 03:00):

Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics in hematology, cardiovascular, and other rare and metabolic indications...

Stats
Šios dienos apimtis	913 528
Vidutinė apimtis	104 775
Rinkos kapitalizacija	0.00
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-0.110
ATR14	£0 (0.00%)

Silence Therapeutics PLC Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Silence Therapeutics PLC Finansinės ataskaitos

Annual	2020
Pajamos:	£5.48M
Bruto pelnas:	£1.72M (31.34 %)
EPS:	£-0.398

FY	2020
Pajamos:	£5.48M
Bruto pelnas:	£1.72M (31.34 %)
EPS:	£-0.398

FY	2019
Pajamos:	£244 000
Bruto pelnas:	£0.00 (0.00 %)
EPS:	£-0.261

FY	2018
Pajamos:	£0.00
Bruto pelnas:	£0.00 (0.00 %)
EPS:	£-0.262

Financial Reports:

No articles found.

Silence Therapeutics PLC

Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various product candidates, including SLN124 for the treatment of iron overload disorders; SLN360 for the cardiovascular disease with high lipoprotein; and SLN500 for the treatment of complement-mediated diseases. Silence Therapeutics plc has a strategic collaboration with AstraZeneca to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and collaboration with Genomics England Limited. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.